https://orcid.org/0000-0001-6589-2845
Figures & data
Figure 1. Geographic distribution, speciality and healthcare setting of survey respondents.
Source: physician survey, physician interviews and secondary data. DE: Germany; ES: Spain; FR: France; IT: Italy; NL: the Netherlands; UK: United Kingdom.
Figure 2. ITP treatment paradigm based on current national guidelines [Citation7,Citation9,Citation11–13].
IVIg: intravenous immunoglobulin; TPO-RA: thrombopoietin receptor agonist.
![Figure 2. ITP treatment paradigm based on current national guidelines [Citation7,Citation9,Citation11–13].IVIg: intravenous immunoglobulin; TPO-RA: thrombopoietin receptor agonist.](/cms/asset/97287b77-3c5d-4012-8af6-7e4e4ccc500c/yhem_a_1992945_f0002_oc.jpg)
Figure 3. Proportion of patients with mild, moderate or severe bleeding events and associated days of hospitalization by country.
Data may not sum to 100% due to rounding. Source: physician survey, physician interviews and secondary data. DE: Germany; ES: Spain; FR: France; IT: Italy; ITP: immune thrombocytopenia; NL: the Netherlands; UK: United Kingdom.
Figure 4. Average cost of bleed events for patients with ITP in six European countries.
All UK costs were converted: 1 GBP = 1.106 Euros (01/07/2020). Source: payer interviews and secondary data. ITP: immune thrombocytopenia.
Figure 5. Forecast compound annual growth rate in ITP population by treatment line (a) and by ITP severity (b) over the next 5–10 years*.
*Due to rounding up some values might not sum up to 100%. Source: physician survey, physician survey and secondary data. CAGR%: compound annual growth rate; ITP: immune thrombocytopenia.
Figure 6. Forecast uptake of TPO-Ras by country over the next five years.
Data may not sum to 100% due to rounding. Source: physician survey and secondary data. DE: Germany; ES: Spain; FR: France; IT: Italy; ITP: immune thrombocytopenia; NL: the Netherlands; TPO-RA: thrombopoietin receptor agonist; UK: United Kingdom.
